Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics

Recent innovations in oncology drug discovery reveal a convergent strategy built on biological dependency, protein fate control, and quantitative network analysis. Epigenetic protein degradation enables durable transcriptional rewiring, helicase inhibition exploits synthetic-lethal DNA repair vulnerabilities, and DNA-barcoded interactomics quantifies higher-order protein complexes. Together, these advances redefine precision oncology as a system-level discipline driven by context, modality, and measurable biological consequence.